Exploration of real-world outcomes in patients with previously treated HR+/HER2- and triple negative metastatic breast cancer

Key Points

• Patients with metastatic breast cancer show varying outcomes based on treatment history, particularly in HR+/HER2- and triple negative tumors.
• Key metrics indicate that previously treated patients have distinct survival rates, influencing therapeutic strategies.
• Observational analysis of patients reveals broad trends in treatment effectiveness across multiple outcomes.
• Understanding these outcomes may highlight the need for tailored treatment approaches to improve patient care.